{"id":"W1971512067","doi":"10.1016/j.jcf.2013.12.009","title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","year":2014,"lang":"en","type":"article","venue":"Journal of Cystic Fibrosis","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada); McGill University Health Centre; Montreal Children's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Cystic Fibrosis Foundation","keywords":"Cystic fibrosis; Medicine; Placebo; Double blind; Antagonist; Lung disease; Receptor antagonist; Internal medicine; Lung; Randomized controlled trial; Gastroenterology; Receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001975292,0.0004067467,0.00264652,0.0004758421,0.0001175513,0.00006336028,0.0002487314,0.0001058397,0.00005418069],"category_scores_gemma":[0.002972927,0.0002159073,0.000628809,0.0003503597,0.0005572108,0.0002415714,0.00002731838,0.00020535,7.721511e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001756818,"about_ca_system_score_gemma":0.0004819042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001785841,"about_ca_topic_score_gemma":0.00002411017,"domain_scores_codex":[0.9959467,0.0005125844,0.001772187,0.0003627361,0.0009494558,0.0004563371],"domain_scores_gemma":[0.9904948,0.006510342,0.001406981,0.0004850547,0.0005871903,0.0005156363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830962,0.002732438,0.000860819,0.0004678757,0.001126112,0.000006093272,0.0005232074,0.0003636986,0.007240437,0.00004010857,0.00009159398,0.003451362],"study_design_scores_gemma":[0.948705,0.02594343,0.001118687,0.001322889,0.003125461,0.00004626311,0.000126342,0.01594948,0.003239558,0.00007093953,0.000152162,0.000199773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816425,0.003517322,0.005422835,0.0004356504,0.0001686583,0.008543974,0.0002446303,0.00001220171,0.00001223245],"genre_scores_gemma":[0.9885941,0.0006771497,0.009571921,0.00001456388,0.0004250553,0.0005284847,0.00006440435,0.0000518628,0.00007252909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03439124,"threshold_uncertainty_score":0.8804444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0121357020093496,"score_gpt":0.3139832868791729,"score_spread":0.3018475848698233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}